Brief: Intra-Cellular Therapies Reports Q4 Net Loss Of $0.45 Per Share

Intra-Cellular Therapies

01/03/2023 14:06

March 1 (Reuters) - Intra-Cellular Therapies Inc
 ITCI.O :
    * INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND
FULL-YEAR
2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
    * INTRA-CELLULAR THERAPIES INC - NET LOSS FOR Q4 OF 2022 WAS
$44.0
MILLION COMPARED TO A NET LOSS OF $85.7 MILLION FOR SAME PERIOD
IN 2021
    * INTRA-CELLULAR THERAPIES INC SEES CAPLYTA 2023 NET PRODUCT
SALES
ARE EXPECTED TO BE $430 TO $455 MILLION
    * INTRA-CELLULAR THERAPIES INC - QTRLY NET LOSS PER COMMON
SHARE,
BASIC & DILUTED $0.45

Source text for Eikon:  ID:nGNXbHTy21 
Further company coverage:  ITCI.O 

 ((Reuters.Briefs@thomsonreuters.com;))